Gwenny Fuhler

Gwenny Fuhler
Assistant Professor
room Na-1006
Email: g.fuhler@erasmusmc.nl 
 
From 1994 till 1999 she studied Medical Biology at the University of Groningen, The Netherlands, during which time she did a Master's thesis on the role of tropomyosins in cancer at the Harvard affiliated teaching hospital Beth Israel Deaconess Medical Center, Boston, USA. In 2000 she started here research doctorate program on the impaired neutrophil functions in patients with the pre-leukemic disease Myelodysplasia (MDS) in the department of Hematology at the University Medical Center Groningen, which culminated in the acquisition of a PhD in Medical Sciences in 2005. In 2003 she was awarded a short-term fellowship from the European Molecular Biology Organization (EMBO), which was used to visit the University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth hospitals, UK. As a junior post-doctoral researcher in the department of Hematology at the University Medical Center Groningen, she investigated the mechanisms of impaired migration of blood precursor cells from patients with low-risk MDS. In 2007 she joined the Department of Cell Biology, section Immunology, of the University Medical Center Groningen where she worked on the identification and characterization of the putative stem cell in the blood disease Multiple Myeloma, for which she was awarded a grant from the Gratama-Stichting. This work brought here into contact with Prof. W. Kerr and Prof A. List, whom she later joined at the Lee Moffit Cancer Institute, Tampa, USA in 2008 for a collaborative effort on a project on the role of impaired signalling in MDS and Myeloma cells, work for which she obtained funding from the WES Foundation. As part of this ongoing collaboration, she performed a post-doctoral research project with Prof. Kerr again in his new lab at SUNY Upstate Medical University, Syracuse, USA in 2010. As of 2010, she is a senior research staff member of the department of Gastroenterology and Hepatology of the Erasmus University Medical Center, Rotterdam, where she received a fellowship of the Dutch Cancer Society for my studies into the role of phosphatases in cancer. Here current interests centers around the host-microbial actions contributing to human gastrointestinal diseases. These studies include:

1) The role of the intestinal microbiota in intestinal inflammation in patients with Inflammatory bowel diseases (IBD).
Inflammatory bowel disease is a complex disease, arising as a consequence of impaired interaction between the host immune system in genetically susceptible individuals. We aim to study these different components contributing to IBD pathology, in order to find potential targets for patient stratification, therapy, or diagnosis.

2) The potential use of intestinal microbiome detection for colorectal cancer (CRC) screening.
Colorectal cancer is the third most commonly diagnosed cancer in the world, and follows a well-described adenoma to carcinoma sequence which is accompanied by an accumulation of mutations in the APC, KRAS, SMAD4 and TP53 genes. Identification and treatment of colorectal cancer still requires improvement - it is as yet the fourth leading cause of cancer, and recurrence/metastasis of disease is an obvious problem.

3) The role of Helicobacter pylorshe interaction with gastric epithelium during gastric metaplasia and the contribution of endoplasmic reticulum stress therein. 
Intestinal metaplasia of the gastric mucosa is considered a precancerous lesion which may progress to gastric cancer. The primary cause of gastric cancer is considered to be infection with the pathogen Helicobacter pylori. The exact mechanisms of H. pylorshe induced carcinogenesis, and its role in progression from metaplasia to carcinoma remain to be elucidated.


 
 
Selected publications

  • J. Scholma, G.M. Fuhler, J Joore, M. Hulsman, S. Schivo, A.F. List, M.J. Reinders, M.P. Peppelenbosch, J.N. Post.
    Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots.
    Sci Rep. 2016 May 26;6:26695
  • E. Hoekstra, A.M. Das, M. Swets, W. Cao, C.J. van der Woude, M.J. Bruno, M.P. Peppelenbosch, P.J. Kuppen, T.L. Ten Hagen, G.M. Fuhler.
    Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.
    Oncotarget 2016  doi: 10.18632/oncotarget.7829.
  • R.R. Ruela-de-Sousa, E. Hoekstra, A.M. Hoogland, K.C. Souza Queiroz, M.P. Peppelenbosch, A.P. Stubbs, K. Pilazzaro-Rocha, G.J. van Leenders, G. Jenster, H. Aoyama, C.V. Ferreira, G.M. Fuhler.
    Low-molecular weight protein tyrosine phosphatase predicts prostate cancer outcome by increasing the metastatic potential.
    Eur Urol. 2016 Apr;69(4):710-9. 
  • E. Hoekstra, L. L. Kodach, A.M. Dash, R. R. Ruela-se-Sousa, C.V. Ferreira, J.C. Hardwick, C. J. van der Woude, M. P. Peppelenbosch, G.M. Fuhler.
    Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.
    Oncotarget 2015. 6(10):8300-12
  • W.K. Utomo, M. de Vries, D. C. van Rijckevorsel, M.P. Peppelenbosch, H. van Goor, G. M. Fuhler.
    Cannabinoid receptor agonist Namisol does not affect cytokine levels in chronic pancreatitis patients.
    Am. J. Gastroenterol. 2015; 110(8); 1244-5 
  • V. Nuij G.M. Fuhler, A.J. Edel, R.J. Ouwendijk, M.C. Rijk, R. Beukers, R. Quispel, A.J. van Tilburg, T.J. Tang, H. Smalbraak, K.F. Bruin, F. Lindernburg, L. Peyrin-Biroulet, C.J. van der Woude; Dutch Delta IBD Group. Benefit of earlier anti-TNF treatment on IBD disease complications?
    J. Crohns Colitis 2015 Nov;9(11):997-1003.
  • K. Parikh, L. Zhou, R. Somasundaram, G.M. Fuhler, J.J. Deuring, T. Blokzijl, A. Regeling, E.J. Kuipers, R.K. Weersma, V.J. Nuij, M. Alves, L. Vogelaar, L. Visser, C. de Haar, K.K. Krishnadath, C.J. van der Woude, G. Dijkstra, K.N. Faber, M.P. Peppelenbosch.
    Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's disease.
    Sci. Transl. Med. 2014,  23;6(233):233ra53
  • J.J. Deuring, G.M. Fuhler, S.R. Konstantinov, M.P. Peppelenbosch, E.J. Kuipers, C. de Haar, C.J. van der Woude.
    Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn's disease.
    Gut 2014 (63(7):1081-91.
  • G.M. Fuhler, R. Brooks, B. Toms, S. Iyer, E.A. Gengo, M.Y. Park, M. Gumbleton, D.R. Viernes, J.D. Chisholm, W.G. Kerr.
    Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.
    Mol. Med. 2012 18(1):65-75
  • R. Somasundaram, J.J. Deuring, C.J. van der Woude, M.P. Peppelenbosch, G.M. Fuhler.
    Linking risk conferring mutations in MCF4 to functional consequences in Crohn's disease.
    Gut. 2012 Jul;61(7):1097

Pubmed search for G. Fuhler